- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Marquette plans purchase of Corometrics
Marquette Electronics reported signing an agreement this month to purchase Corometrics Medical Systems from parent American Home Products. Corometrics markets Aloka's line of ob/gyn ultrasound scanners.Milwaukee-based Marquette, which manufactures
Marquette Electronics reported signing an agreement this month to purchase Corometrics Medical Systems from parent American Home Products. Corometrics markets Aloka's line of ob/gyn ultrasound scanners.
Milwaukee-based Marquette, which manufactures patient monitoring devices, will continue to maintain the OEM relationship with Aloka, according to the company.
Japan-based Aloka tied with GE for second place in the U.S. ob/gyn segment in 1992 with an 18% market share (SCAN 7/28/93). Aloka assumed direct sales and marketing of its scanners outside the ob/gyn segment in 1990 (SCAN 8/15/90).
Marquette will acquire Wallingford, CT-based Corometrics for $73 million. The deal is subject to the approval of the board of American Home Products, as well as federal antitrust authorities.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
